Clinical and Biological Significance of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes As Biomarkers in Colorectal Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Sep 15

PMID 28903450

Citations 80

Authors

Shiyu Jia

Rui Zhang

Ziyang Li

Jinming Li

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) has been the fourth leading cause of cancer-related mortality worldwide. Owing to clonal evolution and selection, CRC treatment needs multimodal therapeutic approaches and due monitoring of tumor progression and therapeutic efficacy. Liquid biopsy, involving the use of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes, may offer a promising noninvasive alternative for diagnosis and for real-time monitoring of tumor evolution and therapeutic response compared to traditional tissue biopsy. Monitoring of the disease processes can enable clinicians to readily adopt a strategy based on optimal therapeutic decision-making. This article provides an overview of the significant advances and the current clinical and biological significance of CTCs, ctDNA, and exosomes in CRC, as well as a comparison of the main merits and demerits of these three components. The hurdles that need to be resolved and potential directions to be followed with respect to liquid biopsies for detection and therapy of CRC are also discussed.

Citing Articles

Application of CellSearch technique in detection of peripheral blood circulating tumour cell count in patients with head and neck cancer and its association with prognosis.

Li H, Li P, Li F, Wang T Oncol Lett. 2024; 29(2):100.

PMID: 39717066 PMC: 11664308. DOI: 10.3892/ol.2024.14846.

Circulating Tumor cells and multiple indicators combined to identify the risk of poorer prognosis in patients with resected non-small cell lung cancer.

Song J, Ye X, Peng Q, Ying X, Xiao H BMC Cancer. 2024; 24(1):1491.

PMID: 39627742 PMC: 11616275. DOI: 10.1186/s12885-024-13245-y.

Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: A Review of Methods and Applications.

Dubrovsky G, Ross A, Jalali P, Lotze M Int J Mol Sci. 2024; 25(20).

PMID: 39456796 PMC: 11507494. DOI: 10.3390/ijms252011013.

MicroRNA‑24 alleviates colorectal cancer progression via a rs28382740 single nucleotide polymorphism in the long noncoding region of X‑linked inhibitor of apoptosis protein.

Tian Y, Huang C, Liu C, Yang S, Hung C, Lin K Oncol Lett. 2024; 28(6):591.

PMID: 39417038 PMC: 11481099. DOI: 10.3892/ol.2024.14724.

Role of Exosomes in Salivary Gland Tumors and Technological Advances in Their Assessment.

Nieszporek A, Wierzbicka M, Labedz N, Zajac W, Cybinska J, Gazinska P Cancers (Basel). 2024; 16(19).

PMID: 39409917 PMC: 11475412. DOI: 10.3390/cancers16193298.

References

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

Kosmidou V, Oikonomou E, Vlassi M, Avlonitis S, Katseli A, Tsipras I . Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. Hum Mutat. 2013; 35(3):329-40. DOI: 10.1002/humu.22496. View

Jain M, Olsen H, Paten B, Akeson M . The Oxford Nanopore MinION: delivery of nanopore sequencing to the genomics community. Genome Biol. 2016; 17(1):239. PMC: 5124260. DOI: 10.1186/s13059-016-1103-0. View

Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J . Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2004; 113(5):752-60. DOI: 10.1002/ijc.20657. View

Church T, Wandell M, Lofton-Day C, Mongin S, Burger M, Payne S . Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2013; 63(2):317-25. PMC: 3913123. DOI: 10.1136/gutjnl-2012-304149. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009; 20(7):1223-9. DOI: 10.1093/annonc/mdn786. View

Sarioglu A, Aceto N, Kojic N, Donaldson M, Zeinali M, Hamza B . A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015; 12(7):685-91. PMC: 4490017. DOI: 10.1038/nmeth.3404. View

10.

Zhang R, Ding J, Han Y, Yi L, Xie J, Yang X . The reliable assurance of detecting somatic mutations in cancer-related genes by next-generation sequencing: the results of external quality assessment in China. Oncotarget. 2016; 7(36):58500-58515. PMC: 5295447. DOI: 10.18632/oncotarget.11306. View

11.

Sastre J, Maestro M, Gomez-Espana A, Rivera F, Valladares M, Massuti B . Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist. 2012; 17(7):947-55. PMC: 3399651. DOI: 10.1634/theoncologist.2012-0048. View

12.

Bedin C, Enzo M, Del Bianco P, Pucciarelli S, Nitti D, Agostini M . Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. Int J Cancer. 2016; 140(8):1888-1898. DOI: 10.1002/ijc.30565. View

13.

Lo Y, Zhang J, Leung T, Lau T, Chang A, Hjelm N . Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999; 64(1):218-24. PMC: 1377720. DOI: 10.1086/302205. View

14.

Deneve E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daures J . Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem. 2013; 59(9):1384-92. DOI: 10.1373/clinchem.2013.202846. View

15.

Janowska-Wieczorek A, Marquez-Curtis L, Wysoczynski M, Ratajczak M . Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion. 2006; 46(7):1199-209. DOI: 10.1111/j.1537-2995.2006.00871.x. View

16.

Harouaka R, Kang Z, Zheng S, Cao L . Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther. 2013; 141(2):209-21. PMC: 3947247. DOI: 10.1016/j.pharmthera.2013.10.004. View

17.

Gervasoni A, Sandri M, Nascimbeni R, Zorzino L, Cassatella M, Baglioni L . Comparison of three distinct methods for the detection of circulating tumor cells in colorectal cancer patients. Oncol Rep. 2011; 25(6):1669-703. DOI: 10.3892/or.2011.1231. View

18.

Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E . Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015; 75(5):892-901. DOI: 10.1158/0008-5472.CAN-14-2613. View

19.

Karapetis C, Khambata-Ford S, Jonker D, OCallaghan C, Tu D, Tebbutt N . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-65. DOI: 10.1056/NEJMoa0804385. View

20.

Spindler K, Pallisgaard N, Andersen R, Jakobsen A . Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer. 2014; 135(9):2215-22. DOI: 10.1002/ijc.28863. View